United Therapeutics Corp
UTHR
Market Cap$14.38B
Close$
$898.26
181.7% upside
Current Fair Value
181.7% upsideUndervalued by 181.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.38 Billion |
|---|---|
| Enterprise Value | $12.68 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $26.44 |
| Beta | 0.58 |
| Outstanding Shares | 44,900,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 11.82 |
|---|---|
| PEG | 232.4 |
| Price to Sales | 4.83 |
| Price to Book Ratio | 2.11 |
| Enterprise Value to Revenue | 4.24 |
| Enterprise Value to EBIT | 8.23 |
| Enterprise Value to Net Income | 10 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About United Therapeutics Corp
920 employees
CEO: Martine Rothblatt United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power o...